Skip to content

Alcoholism Treatment Quarterly

ISSN 0734-7324

2 papers in the library · publishing 1992-2025

Papers

Evaluating the Effectiveness of Psychedelic-Assisted Therapy in Treating Alcohol Use Disorders: A Review

Alcoholism Treatment Quarterly May 2, 2025 Ritika Shah, Ashish Sarangi

A narrative review of 71 studies on psychedelic-assisted therapy for alcohol use disorder (AUD) finds that psilocybin and LSD are associated with significant reductions in alcohol consumption, enhanced emotional regulation, and sustained mental health improvements over 6 to 32 weeks. A meta-analysis of six trials indicated that a single dose of LSD outperformed traditional medications like naltrexone and acamprosate in promoting long-term abstinence. The effects are thought to involve serotonin 2A receptor agonism and neuroplasticity in the prefrontal cortex. The review emphasizes psychedelic-assisted therapy as a promising alternative or adjunct to standard AUD treatments, especially when combined with behavioral therapies like Motivational Enhancement Therapy.

The combination of psychedelic and aversive approaches in alcoholism treatment: The affective contra-attribution method

Alcoholism Treatment Quarterly January 1, 1992

A three-stage alcoholism treatment called Affective Contra-Attribution (ACA) combines introductory psychotherapy, psychedelic treatment with ketamine (along with bemegride and aethimizol), and group discussion of the psychedelic experience. The psychedelic stage involves psychotherapeutic dialogue during negative hallucinatory emotional states induced by subanesthetic ketamine doses. Compared to a more traditional therapy, the ACA method is more effective.